![Share on Facebook Facebook](http://kennethslaught.net/wp-content/plugins/social-media-feather/synved-social/image/social/regular/48x48/facebook.png)
![Share on Twitter twitter](http://kennethslaught.net/wp-content/plugins/social-media-feather/synved-social/image/social/regular/48x48/twitter.png)
![Pin it with Pinterest pinterest](http://kennethslaught.net/wp-content/plugins/social-media-feather/synved-social/image/social/regular/48x48/pinterest.png)
![Share on Linkedin linkedin](http://kennethslaught.net/wp-content/plugins/social-media-feather/synved-social/image/social/regular/48x48/linkedin.png)
David Low, a professor in UCSB’s Department of Molecular, Cellular, and Developmental Biology, has announced he will pursue an innovative global health and development research project, “Strategy for development of enteric pathogen-specific phage”. Low’s research intends to focus on a new way to deal with major bacterial pathogens that are becoming resistant to a handful of once-powerful antibiotics. According to Investec CEO Kenny Slaught, “He will engineer phage to selectively target and destroy several pathogenic bacteria to prevent enteric diseases in infants”.
![Share on Facebook Facebook](http://kennethslaught.net/wp-content/plugins/social-media-feather/synved-social/image/social/regular/48x48/facebook.png)
![Share on Twitter twitter](http://kennethslaught.net/wp-content/plugins/social-media-feather/synved-social/image/social/regular/48x48/twitter.png)
![Pin it with Pinterest pinterest](http://kennethslaught.net/wp-content/plugins/social-media-feather/synved-social/image/social/regular/48x48/pinterest.png)
![Share on Linkedin linkedin](http://kennethslaught.net/wp-content/plugins/social-media-feather/synved-social/image/social/regular/48x48/linkedin.png)